Olema Pharmaceuticals, Inc.

Olema Oncology, operating as Olema Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of targeted therapies for women's cancers, particularly breast cancer and other endocrine-driven cancers. The company's mission is to transform the standard of care and improve outcomes for patients living with breast cancer and beyond. Headquartered in San Francisco, California, Olema Oncology also maintains operations in Cambridge, Massachusetts.

Olema Oncology's pipeline features two primary product candidates: palazestrant (OP-1250) and OP-3136. Palazestrant is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD), designed to block estrogen receptor activity regardless of ESR1 mutation status. It is currently being evaluated in pivotal Phase 3 clinical trials, OPERA-01 and OPERA-02, for ER+/HER2- metastatic breast cancer, and has received FDA Fast Track designation. OP-3136 is an earlier-stage, potent, selective oral inhibitor of lysine acetyltransferase 6 (KAT6), which is being investigated in Phase 1 clinical trials for breast and other solid tumors.

In recent news, Olema Oncology appointed Prakash Raman, Ph.D., to its Board of Directors in April 2026, bringing extensive biopharmaceutical leadership experience to the company. The company is also slated to present initial clinical data for OP-3136 at the 2026 ASCO Annual Meeting and preclinical data for both palazestrant and OP-3136 at the 2026 AACR Annual Meeting. Olema Oncology has strengthened its financial position through a $250 million funding round and a collaboration with Novartis for the Phase 3 OPERA-02 trial, which will evaluate palazestrant in combination with ribociclib. Sean P. Bohen, M.D., Ph.D., serves as the President and CEO, guiding the company's efforts to advance its clinical programs and enhance its market positioning in oncology.

Latest updates

Olema Oncology Adds Seasoned BD Vet to Board Amid Key Trial Data Approach

Event summary

  • Olema Oncology appointed Prakash Raman, Ph.D., to its Board of Directors, effective April 29, 2026.
  • Raman currently serves as CEO of InduPro Therapeutics, a protein therapeutics company.
  • He previously held executive roles at Ribon Therapeutics and Novartis, including VP, Global Head of NIBR Business Development and Licensing.
  • Olema is preparing for pivotal data from the OPERA-01 trial this fall and advancing its KAT6 inhibitor, OP-3136, in Phase 1.
  • Raman also serves on the Board of Directors of Black Diamond Therapeutics since April 2024.

The big picture

The appointment of a seasoned business development executive like Raman signals Olema's intent to accelerate its growth trajectory and potentially explore strategic acquisitions or partnerships. This move comes as the company approaches a critical inflection point with the OPERA-01 trial data release, which will heavily influence investor sentiment and future development plans. Raman’s experience navigating complex deals and portfolio strategy at Novartis and Flagship Pioneering could prove invaluable as Olema aims to become a fully integrated oncology company.

What we're watching

Governance Dynamics
Raman's extensive BD background suggests Olema may be accelerating M&A or partnership discussions, potentially shifting the company's strategic direction beyond its current pipeline.
Clinical Execution
The OPERA-01 trial data release will be critical; a negative outcome could trigger a reassessment of the palazestrant program and Raman's strategic advice.
Pipeline Expansion
Given Raman’s history of identifying and integrating acquisitions at Novartis, Olema’s ability to leverage his expertise in sourcing and developing new assets will be key to long-term growth.
CID: 993